Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies

Arthritis Care and Research

Volumn 49, Issue 3, 2003, Pages 399-412

  Reveille, John D ^a   Solomon, Daniel H ^b   Schur, Peter ^b   Kavanaugh, Arthur ^c   Sherrer, Yvonne R S ^d   Lahita, Robert ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Ctr Rheumatology Immunol Arthr   (United States)

^e ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; SCL 70 ANTIBODY; UNCLASSIFIED DRUG;

DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOLOGICAL PROCEDURES; LABORATORY TEST; METHODOLOGY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SCLERODERMA;

EID: 0038651202     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11113     Document Type: Review

References (114)

1. Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988;31:525-32.
2. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr. Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211-7.
3. Blaszczyk M, Jarzabek-Chorzelska M, Jablonska S, Chorzelski T, Kolacinska-Strasz Z, Beutner EH, et al. Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations. Br J Dermatol 1990;123:421-30.
4. Reddy R, Tan EM, Henning D, Nohga K, Busch H. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983;258:1383-6.
5. Reimer G, Rose KM, Scheer U, Tan EM. Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 1987;79:65-72.
6. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993;91:1399-404.
7. Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993;119:1005-13.
8. Hayward R, Wilson M, Tunis S, Bass E, Guyatt G, for the Evidenced-Based Medicine Working Group. Users' guide to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? JAMA 1995;274:570-4.
9. Wilson M, Hayward R, Tunis S, Bass E, Guyatt G, for the Evidenced-Based Medicine Working Group. Users' guide to the medical literature. VIII. How to use clinical practice guidelines. B. What are the recommendations and will they help you in caring for your patients? JAMA 1995;274:1630-2.
10. Jaeschke R, Guyatt G, Sackett DL, for the Evidenced-Based Medicine Working Group. Users' guide to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? JAMA 1994;271:389-91.
11. Jaeschke R, Guyatt G, Sackett DL, for the Evidenced-Based Medicine Working Group. Users' guide to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA 1994;271:703-7.
12. Van Walraven C, Naylor CD. Do we know what inappropriate laboratory utilization is? JAMA 1998;280:550-8.
13. Fennell RHJ, Rodnan GP, Vazquez JJ. Variability of tissuelocalizing properties of serum from patients with different disease states. Lab Invest 1962;11:24-31.
14. Beck JS, Anderson JR, Gray KG, Rowell NR. Antinuclear and precipitating autoantibodies in progressive systemic sclerosis. Lancet 1963;2:1188-90.
15. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514-22.
16. Shero JH, Bordwell B, Earnshaw WC. High titers of auto-antibodies to topoisomerase I (SCL-70) in sera from scleroderma patients. Science 1986;14:737-40.
17. Maul GG, French BT, van Venrooij WJ, Jimenez SA. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci U S A 1986;83:5145-9.
18. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617-25.
19. Sullivan KF, Hechenberger M, Masri K. Human CENP-A contains a histone H3 related histone fold domain that is required for targeting to the centromere. J Cell Biol 1994;127:581-92.
20. Sugimoto K, Muro Y, Himeno M. Anti-helix-loop-helix domain antibodies: discovery of autoantibodies that inhabit DNA binding activity of human centromere protein B (CENP-B). J Biochem 1992;111:478-83.
21. Masumoto H, Masukata H, Muro Y, Nozaki N, Okazaki T. A human centromere antigen (CENP-B) interacts with a short specific sequence in alphoid DNA, a human centromeric satellite. J Cell Biol 1989;109:1963-73.
22. Sugimoto K, Kuriyama K, Himeno M, Muro Y. Epitope mapping of human centromere autoantigen centromere protein C (CENP-C): heterogeneity of anti-CENP-C response in rheumatic diseases. J Rheumatol 1998;25:474-81.
23. Saitoh H, Tomkiel J, Cooke CA, Ratrie III H, Mauer M, Rothfield NF, et al. CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell 1992;70:115-25.
24. Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeleton 1993;26:214-26.
25. Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol 1995;130:507-18.
26. Ritchie RF: Antinucleolar antibodies: their frequency and diagnostic association. N Engl J Med 1970;282:1174-8.
27. Reichlin M, Maddison PJ, Targoff IN, Bunch T, Arnett FC, Sharp GC, et al. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol 1984;4:40-4.
28. Kipnis RJ, Craft J, Hardin JA. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. Arthritis Rheum 1990;33:1431-7.
29. Lischwe MA, Ochs RL, Reddy R, Cook RG, Yeoman LC, Tan EM, et al. Purification and partial characterization of a nucleolar scleroderma antigen (Mr=34,000; pI=8.5) rich in Ng,Ng-dimethylarginine. J Biol Chem 1985;260:14304-10.
30. Hirakata M, Okano Y, Pati U, Suwa A, Medsger TA Jr, Hardin JA, et al. Identification of autoantibodies to RNA polymerase II: occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. J Clin Invest 1993;91:2665-72.
31. Rattner JB, Rees J, Arnett FC, Reveille JD, Goldstein R, Fritzler MJ. The centromere kinesin-like protein, CENP-E: an autoantigen in systemic sclerosis. Arthritis Rheum 1996;39:1355-61.
32. Earnshaw W, Bordwell B, Marino C, Rothfield N. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest 1986;77:426-30.
33. Rothfield N, Whitaker D, Bordwell B, Weiner E, Senecal JL, Earnshaw W. Detection of anticentromere antibodies using cloned autoantigen CENP-B. Arthritis Rheum 1987;30:1416-9.
34. Russo K, Hoch S, Dima C, Varga J, Teodorescu M. Circulating anti-centromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2000;27:142-8.
35. Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999;42:455-64.
36. Aeschlimann A, Meyer O, Bougeois P, Haim T, Belmatoug N, Palazzo E, et al. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis 1989;48:992-7.
37. Hildebrandt S, Weiner E, Senecal JL, Noell S, Daniels L, Earnshaw WC, et al. The IgG, IgM and IgA isotypes of anti-topoisomerase-I and anticentromere autoantibodies. Arthritis Rheum 1990;33:724-7.
38. Tsay GJ, Fann RH, Hwang J. Specificity of anti-Scl-70 anti-bodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus. J Rheumatol 1990;17:1314-9.
39. Cram DS, Fisicaro N, McNeilage LJ, Coopel RL, Harrison LC. Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins. J Immunol 1993;151:6872-81.
40. Bizzaro N, Tonutti E, Villalta D, Bassetti D, Tozzoli R, Manoni F, et al. Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantobodies: results of a multicenter study. Clin Chem 2000;46:1681-5.
41. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with progressive systemic sclerosis. Arthritis Rheum 1988;31:196-203.
42. Bernstein RM, Steigerwald JC, Tan EM. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 1982;48:43-51.
43. Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992;35:95-100.
44. Vazquez-Abad D, Wallace S, Senecal JL, Joyal F, Roussin A, Earnshaw WC, et al. Anticentromere autoantibodies: evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. Arthritis Rheum 1994;37:248-52.
45. Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL. The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 1984;59:700-6.
46. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abauf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjogren syndrome and scleroderma. Br J Haematol 1987;66:45-7.
47. Sato S, Fujimoto M, Inh H, Takehara K. Antibodies to centromere and centriole in scleroderma spectrum disorders. Dermatology 1994;189:23-6.
48. Chan HL, Lee YS, Hong HS, Kuo TT. Anticentromere antibodies (ACA): clinical distribution and disease specificity, Clin Exp Dermatol 1994;19:298-302.
49. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989;32:54-60.
50. Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C, et al. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear anti-bodies in patients with early rheumatic diseases. J Rheumatol 1991;18:1340-3.
51. Catoggio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983;42:23-7.
52. Kallenberg CGM, Pastoor GW, Wouda AA, The TH. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 1982;41:382-7.
53. Ferri C, Bernini L, Cecchetti R, Latorraca A, Marotta G, Pasero G, et al. Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol 1991;18:1826-32.
54. Iwai T, Muro Y, Sugimoto K, Matsumura M, Ohashi M. Clinical features of anti-chromo antibodies associated with anti-centromere antibodies. Clin Exp Immunol 1996;105:285-90.
55. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere anti-bodies and antibodies to topoisomerase I. Arthritis Rheum 1988;31:378-85,
56. Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA. Antinuclear antibodies in scleroderma, mixed connective tissue disease and primary Raynaud's phenomenon [published erratum appears in Clin Rheum 1988;7:277]. Clin Rheumatol 1988;7:80-6.
57. Tuffanelli DL, McKeon F, Kleinsmith DM, Burnham TK, Kirschner M. Anticentromere and anticentriole antibodies in the scleroderma spectrum. Arch Dermatol 1983;119:560-6.
58. Moutsopoulos HM, Giotaki H, Maddison PJ, Mavridis AC, Drosos AA, Skopouli FN. Antibodies to cellular antigens in Greek patients with autoimmune rheumatic diseases: anti-Ro(SSA) antibody a possible marker of penicillamine-D intolerance. Ann Rheum Dis 1984;43:285-7.
59. Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE, et al. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 1996;90:223-30.
60. Sarkozi J, Bookman AAM, Lee P, Keystone EC, Fritzler MJ. Significance of anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med 1987;83:893-8.
61. Catoggio LJ, Skinner RP, Maddison PJ. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population. Rheumatol Int 1983;3:19-21.
62. Ruffatti A, Peserico A, Glorioso S, Fiocco U, Rossi L, Gambari P, et al. Anticentromere antibody in localized scleroderma. J Am Acad Dermatol 1986;15:637-42.
63. Riboldi P, Asero R, Origgi L, Crespi S, Meroni PL, Sguotti C, et al. Antinuclear antibodies in progressive systemic sclerosis. Clin Exp Rheumatol 1985;3:205-11.
64. Manoussakis MN, Constantopoulos SH, Gharavi AE, Moutsopoulos HM. Pulmonary involvement in systemic sclerosis. Chest 1987;92:509-13.
65. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in black South Africans. Rheumatol 1999;38:397-400.
66. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992;35:216-8.
67. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM. Influence of ethnic background on clinical and serologic features of patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-74.
68. Fritzler MJ, Kinsella JD, Garbutt E. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980;69:520-6.
69. Bunn CC, Denton CP, Shi-wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
70. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH. Scl 70 antibody: a specific marker of systemic sclerosis. Br J Dermatol 1986;115:393-401.
71. Tsay GJ, Fann R, Hwang J. Specificity of anti-Scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus. J Rheumatol 1990;1319.
72. Takehara K, Moroi Y, Ishibashi Y. Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol 1985;112:23-33.
73. McHugh NJ, Whyte J, Artlett C, Briggs DC, Stephens CO, Olsen NJ, et al. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol 1994;96:267-74.
74. De Rooij DJ, van de Putte LB, Habets WJ, Verbeek AL, van Venrooij WJ. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Scand J Rheumatol 1988;17:353-64.
75. Hildebrandt S, Weiner ES, Senecal JL, Noell GS, Earnshaw WC, Rothfield NF. Autoantibodies to topoisomerase 1 (Scl-70): analysis by gel diffusion, immunoblot, and enzymelinked immunosorbent assay. Clin Immunol Immunopathol 1990;57:399-41.
76. Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-scl-70 antibodies. Am J Med 1997;103:242-8.
77. Jarzabek-Chorzelska M, Blaszczyk M, Kolacinska-Strasz Z, Jablonska S, Chorzelski T, Maul GG. Are ACA and Scl 70 antibodies mutually exclusive? Br J Dermatol 1990;122:201-8.
78. Reveille JD, Durban E, MacLeod MJ, Goldstein R, Moreda R, Altman RD, et al. Association of amino acid sequences in the HLA-DQB1 first domain with the anti-topoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992;90:973-80.
79. Ruffatti A, Calligaro A, Ferri C, Bombardieri S, Gambari PF, Todesco S. Association of anti-centromere and anti-Scl 70 antibodies in scleroderma: report of two cases. J Clin Lab Immunol 1985;16:227-9.
80. Harvey G, Black C, Maddison P, McHugh N. Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997;24:477-84.
81. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-83.
82. Chang M, Wang R, Yangco D, Sharp G, Komatireddy G, Hoffman R. Analysis of autoantibodies against RNA polymerases using immunoafinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1998;89:71-8.
83. Okano Y, Medsger TA Jr. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990;33:1822-8.
84. Satoh M, Kuwana M, Ogasawara T, Ajmani AK, Langdon JJ, Kimpel D, et al. Associations of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. J Immunol 1994;153:5838-48.
85. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in early stages of the disease. J Rheumatol 1988;15:276-83.
86. Livingston JZ, Scott TE, Wigley FM, Anhalt GJ, Bias WB, McLean RH, et al. Systemic sclerosis (scleroderma): clinical, genetic and serologic subsets. J Rheumatol 1987;14:512-8.
87. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60.
88. Briggs DC, Vaughan RW, Welsh KI, Myers A, Dubois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-2.
89. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13:911-6.
90. Hietarinta M, Ilonen J, Lassila O, Hietaharju A. Association of HLA antigens with anti-Scl-70-antibodies and clinical manifestations of systemic sclerosis (scleroderma). Br Rheumatol 1994;33:323-6.
91. Chandran G, Smith M, Ahern MJ, Roberts-Thompson PJ. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust N Z J Med 1995;25:688-94.
92. Parodi A, Puiatti P, Rebora A. Serological profiles as prognostic clues for progressive systemic scleroderma: the Italian experience. Dermatologica 1991;183:15-20.
93. Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G. Clinical setting of patients with systemic sclerosis by autoantibodies. Clin Rheum 1997;16:378-83.
94. Cassani F, Tosti A, Bianchi FB, Fusconi M, Selleri L, Bafoni L, et al. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies. Clin Exp Rheum 1987;5:23-8.
95. De Rooij DJ, van de Putte LBA, Habets WJ, van VenRooij WJ. Marker antibodies in scleroderma and polymyositis: clinical associations. Clin Rheum 1989;8:231-7.
96. Jacobsen S, Halberg P, Ullman S, van Venrooij WJ, Hoier-Madsen M, Wiik A, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998;37:39-45.
97. Shoenfeld Y, Grunebaum E, Laufer M, Zurgil N, Bakimer R, Lunderschmidt A, et al. Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Isr J Med Sci 1998;32:537-42.
98. Igarashi A, Takehara K, Soma Y, Kikuchi K, Ishibashi Y. Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis. Dermatologica 1990;180:136-40.
99. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999;117:395-402.
100. Diot E, Giraudeau B, Diot P, Degenne D, Ritz L, Guilmot J-L, et al. Is anti-topoisomerse I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999;116:715-20.
101. Fanning G, Welsh K, Bunn C, Du Bois R, Black C. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998;37:201-7.
102. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998;114:801-7.
103. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
104. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992;35:688-93.
105. Genth E, Mierau R, Genetzky P, von Muhlen CA, Kaufman S, von Wilmowsky H, et al. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 1990;33:657-65.
106. Arnett FC, Hirsch TJ, Bias WB, Nishikai M, Reichlin M. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol 1981;8:925-30.
107. Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984;27:1150-6.
108. Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992;71:327-36.
109. Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. Arthritis Rheum 1991;34:68-77.
110. Tramposh HD, Smith CD, Senecal JL, Rothfield NF. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984;27:121-4.
111. Vasquez-Abad D, Russell CA, Cusick SM, Earnshaw WC, Rothfield NF. Longitudinal study of anticentromere and antitopoisomerase-1 isotypes. Clin Immunol Immunopathol 1995;74:257-70.
112. Hildebrandt S, Jackh G, Weber S, Peter HH. A long-term longitudinal isotypic study of antitopoisomerase I autoantibodies. Rheumatol Int 1993;12:231-4.
113. Henry PA, Atamas, SP, Yurovsky VV, Luzina I, Wigley F, White B. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arthritis Rheum 2000;43:2733-42.
114. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000;43:1074-84.